Key Market Indicator:
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Tue, 04.03.2025
https://research-hub.de/companies/Fielmann Group AG
Fielmann reported strong preliminary results for FY24, meeting its outlook and consensus expectations. Sales increased by 15% to EUR 2.3bn, driven by 7% organic growth and an 8% contribution from US acquisitions. Core markets in Central Europe showed solid growth, with Germany (+7%), Austria (+10%) and Spain (+10%) performing well. The US business grew by 11% on a comparable basis to reach sales of EUR 200m. All product categories expanded, with strong growth in corrective eyewear (+7%), sunglasses (+6%) and hearing instruments (+10%). Adjusted EBITDA rose by 23% to EUR 491m, with margins improving to 21.7%. Fielmann plans a dividend increase of 15% and remains focused on achieving its Vision 2025 profitability targets. mwb research’s analysts maintain their BUY rating and their PT of EUR 66.00. The full update can be downloaded under https://www.research-hub.de/companies/Fielmann%20AG
Tue, 04.03.2025
https://research-hub.de/companies/Hensoldt AG
While Hensoldt will benefit from rising defense budgets, its exposure is limited compared to larger, more diversified players like Rheinmetall. Sensors and electronics, Hensoldt’s core business, are important but not the priority in today’s rearmament wave, which favors ammunition, drones, and armored vehicles. Despite ambitious revenue targets, even mwb research’s optimistic CAGR´s fall well below faster-growing peers like Rheinmetall. Long-term, Hensoldt faces limited follow-up demand for key products like the TRML-4D radar and lacks transformative new programs to drive post-2030 growth. With the stock rallying 32% in one month, and trading in line with Rheinmetall — despite weaker growth prospects — mwb research’s analysts downgrade from HOLD to SELL with an unchanged price target of EUR 48.00. The full update can be downloaded under https://www.research-hub.de/companies/Hensoldt%20AG.
Tue, 04.03.2025
Scandinavian Astor Group AB
Company Name:
Scandinavian Astor Group AB
ISIN:
SE0019175274
Reason for the research:
Update
Recommendation:
Buy
from:
04.03.2025
Target price:
SEK 30.00
Target price on sight of:
12 months
Last rating change:
Analyst:
Henry Wendisch
Final Q4 out, gearing up for more; raising est. & PT
Topic: Following Q4 prelims in early [ … ]
Tue, 04.03.2025
Flughafen Wien AG
Company Name:
Flughafen Wien AG
ISIN:
AT00000VIE62
Reason for the research:
Update
Recommendation:
Hold
Target price:
EUR 60.00
Target price on sight of:
12 months
Last rating change:
Analyst:
Henry Wendisch
FY'24 prelims out, solid dividend proposal; chg. est & PT
Topic: Yesterday, FWAG published detailed FY'24 prelims an [ … ]
Tue, 04.03.2025
https://research-hub.de/companies/Vulcan Energy Resources Ltd
Vulcan Energy continues to push forward with its lithium and geothermal energy strategy, successfully mobilizing its V20 drilling rig at the Schleidberg site and launching seismic surveys for BASF’s geothermal project in Ludwigshafen. Despite project financing still in progress, Vulcan maintains strong operational momentum, supported by a solid cash position of EUR 97.1m. With drilling underway and seismic data shaping future expansion, the company remains on track to advance its Phase One execution. mwb research’s analysts reiterate their PT of EUR 12.50 and their BUY rating, reflecting their confidence in Vulcan's ability to fully secure project financing. The previous update can be downloaded under https://www.research-hub.de/companies/research/Vulcan%20Energy%20Resources
Mon, 03.03.2025
https://research-hub.de/companies/BASF SE
BASF reported detailed results for FY 24 that were in line with its preliminary release. Full-year revenues of EUR 65.3bn (-5.3% yoy) were weighed down by lower average sales prices and adverse FX. EBITDA excluding special items (ex-SI) grew only marginally to EUR 7.9bn (+2.4% yoy). However, volumes have been gradually recovering over the past few quarters and prices are stabilising. Management has guided for a modest increase in EBITDA ex-SI to EUR 8.0bn-8.4bn in FY 25 (+4% yoy at the mid point). It is on track with its EUR 2.1bn annual cost savings plan (by FY 26), has tapered its capex guidance, and is now committed to keep the overall distribution to shareholders (dividends+ share buybacks) at least at prior-year levels, targeting cumulative returns of at least EUR 12bn over 2025-28. mwb research’s analysts hold a positive view on BASF. The analysts believe its strategy-centered on portfolio optimisation, expansion in high-growth markets, and robust cost-saving initiatives, will position the company for a sustainable and resilient trajectory. The analysts maintain their BUY rating at an unchanged PT of EUR 58.00. The full update can be downloaded under https://www.research-hub.de/companies/BASF%20SE
Mon, 03.03.2025
https://research-hub.de/companies/Rheinmetall AG
Europe is stepping up defense spending to reduce reliance on the US following the Oval Office discussions on Friday. Rheinmetall is well positioned to benefit, thanks to its scale, leadership in ammunition, tanks, air defense, and drones, and aggressive production expansion. Its fully integrated 155mm production makes it Europe’s lowest cost supplier, with ~25% margins and a ~20% price advantage over competitors. If EU defense spending rises to 3% of GDP, Rheinmetall’s revenues could reach ~EUR 40bn by 2033, with further upside from sector consolidation and Germany’s potential EUR 200bn special defense fund. mwb research’s analysts raise their price target to EUR 1,280.00 (previously EUR 1,115.00) and maintain their BUY rating. The full update can be downloaded under https://www.research-hub.de/companies/Rheinmetall%20AG
Mon, 03.03.2025
https://research-hub.de/companies/MS Industrie AG
MS Industrie announced a significant step forward in its off-road diversification, with its subsidiary MS XTEC securing a major contract extension at the beginning of the year. The agreement, effective through 2030 for both Europe and the US, includes an expanded product portfolio and is projected to generate over EUR 100m in business over the next six years. This achievement is especially important as MS Industrie remains largely dependent on the on-road truck market, which contributes 71% of its revenue. The company plans to reduce this dependency to 50% by 2030. With signs of recovery in the on-road market, marked by increasing demand and low truck inventories, growth may surpass expectations. mwb research’s analysts maintain their BUY rating and target price of EUR 2.40, with potential for upward revisions should the recovery gain momentum. The full update can be downloaded under https://research-hub.de/companies/ms-industrie-ag
Mon, 03.03.2025
SFC Energy AG
Company Name:
SFC Energy AG
ISIN:
DE0007568578
Reason for the research:
Update
Recommendation:
Buy
from:
03.03.2025
Target price:
31,00 Euro
Target price on sight of:
12 Monate
Last rating change:
16.02.2021: Hochstufung von Hinzufügen auf Kaufen
Analyst:
Dr. Karsten von Blumenthal
First Berlin Equity Research hat ein Res [ … ]
Mon, 03.03.2025
https://research-hub.de/companies/Viromed Medical AG
Viromed provided an update on the progress of its two main products, ViroCAP and PulmoPlas. The classification of ViroCAP as a Class 2a medical device is on track, with certification expected in 2025. The device, which uses Cold Atmospheric Plasma (CAP) technology to treat wounds, has antimicrobial properties that can inactivate viruses, bacteria, germs and spores. Series production of ViroCAP will begin with an initial batch of 1,000 units for dermatology and veterinary medicine, manufactured in partnership with relyon plasma (TDK Electronics). Meanwhile, PulmoPlas, designed to prevent and treat ventilator-associated pneumonia (VAP) in intensive care, is also progressing as expected. A study led by Prof. Hortense Slevogt is expected to be completed in Q2 2025, after which Viromed plans to apply for special approval from the German Federal Institute for Drugs and Medical Devices in Q3 2025. Given the strong commercialization prospects of Viromed’s CAP technology, mwb research’s analysts reiterate their Spec. BUY rating with a target price of EUR 6.90. The full update can be downloaded under https://www.research-hub.de/companies/Viromed%20Medical%20AG